INCY - Incyte Corporation | StockAlert.pro

Stock Details

Incyte Corporation (INCY), a prominent company in the trade & services sector within the services-commercial physical & biological research industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $83.10. Over the past 52 weeks, it has ranged between $53.56 and $87.99. This places the current price at 94.4% of its 52-week high and 55.2% above its 52-week low. Recent trading volume was recorded at 1,774,980. The International Securities Identification Number (ISIN) for this stock is US45337C1027.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

20.00

Near market average

Forward P/E

14.27

Earnings expected to grow

PEG Ratio

0.15

Potentially undervalued

Price to Book

3.96

EV/EBITDA

10.43

EPS (TTM)

$4.23

Price to Sales

3.60

Beta

0.72

Less volatile than market

How is INCY valued relative to its earnings and growth?

Incyte Corporation trades at a P/E ratio of 20.00, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 14.27 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.15 suggests the stock may be undervalued relative to its growth rate.

What is INCY's risk profile compared to the market?

With a beta of 0.72, Incyte Corporation is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 3.96 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

19.00%

Operating Margin

25.60%

Return on Equity

24.30%

Return on Assets

11.50%

Revenue Growth (YoY)

16.50%

Earnings Growth (YoY)

6.70%

How profitable and efficient is INCY's business model?

Incyte Corporation achieves a profit margin of 19.00%, meaning it retains $19.00 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 25.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 24.30% and ROA at 11.50%, the company generates strong returns on invested capital.

What are INCY's recent growth trends?

Incyte Corporation's revenue grew by 16.50% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 6.70% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry averages for proper context.

Company Size & Market

Shares Outstanding

195.28M

Book Value/Share

$21.49

Asset Type

Common Stock

What is INCY's market capitalization and position?

Incyte Corporation has a market capitalization of $16.52B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 195.28M shares outstanding, the company's ownership is relatively concentrated. As a participant in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry, it competes with other firms in this sector.

How does INCY's price compare to its book value?

Incyte Corporation's book value per share is $21.49, while the current stock price is $83.10, resulting in a price-to-book (P/B) ratio of 3.87. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$81.09

2.42% downside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

How reliable are analyst predictions for INCY?

27 analysts cover INCY with 41% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $81.09 implies -2.4% downside, but targets are often adjusted to follow price moves rather than predict them.

What is the Wall Street consensus on INCY?

Current analyst recommendations:2 Strong Buy, 9 Buy, 15 Hold, 1 Sell, 0The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Sep 1, 2025, 05:21 AM

Incyte Corporation (INCY) Stock